<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Potential advantages and disadvantages of HDAs (host targeted antivirals)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Benefits</th>
    <th align="left">Risks</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Broad-spectrum activity against different virus types that use the same host target</td>
    <td align="left">Potential of host pathway-related toxicity</td>
   </tr>
   <tr>
    <td align="left">Pan-genotype/serotype coverage</td>
    <td align="left">Host/population-specific polymorphisms on differential host target expression</td>
   </tr>
   <tr>
    <td align="left">High barrier to the development of genetic resistance</td>
    <td align="left">Poor translation of in vitro to in vivo (animal models)</td>
   </tr>
   <tr>
    <td align="left">Numerous putative drug targets for cross-class combination therapy</td>
    <td align="left">Complex mechanism of action—Deconvolution of target and target-specific effects challenging</td>
   </tr>
   <tr>
    <td align="left">Can be available before epidemics and pandemics for emerging/new viruses</td>
    <td align="left">Possibility of redundant host mechanisms that ease virus dependence on select target</td>
   </tr>
   <tr>
    <td align="left">Potential for preemptive development of agents before a realized viral threat</td>
    <td align="left">May require direct-acting antivirals as a combination therapy for maximum benefit</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
